← Eichor
Study identifier: NCT06715020 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

Condition: Breast Cancer  ·  Sponsor: Peking University Cancer Hospital & Institute

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The objective of the study is to construct a noninvasive approach 68Ga-TTP PET/CT to detect the TROP2 expression of tumor lesions in patients with breast tumors and evaluate the efficacy of ADC drug therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Zhi Yang  ·  010-88196196  ·  pekyz@163.com

Guojun Zhang  ·  0871-68231187  ·  zhangguojun@kmmu.edu.cn;

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Cancer Hospital & InstituteBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06715020